OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

OptimizeRx (NASDAQ:OPRX - Free Report) had its price target increased by Stifel Nicolaus from $12.50 to $16.00 in a report published on Monday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other equities research analysts also recently commented on the company. JMP Securities increased their price objective on OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a report on Tuesday, May 13th. B. Riley reissued a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Citigroup reissued an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $10.81.

OptimizeRx Stock Down 1.0%

Shares of OPRX traded down $0.15 during mid-day trading on Monday, hitting $15.05. 221,530 shares of the company's stock were exchanged, compared to its average volume of 293,757. The company has a market cap of $278.35 million, a PE ratio of -11.32 and a beta of 1.34. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $15.63. The company has a 50-day simple moving average of $10.56 and a 200 day simple moving average of $7.51. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.19. The company had revenue of $21.93 million during the quarter, compared to analysts' expectations of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. On average, research analysts forecast that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the business's stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now directly owns 389,452 shares of the company's stock, valued at $2,959,835.20. This trade represents a 472.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. acquired a new stake in OptimizeRx during the 4th quarter valued at $25,000. GAMMA Investing LLC acquired a new stake in OptimizeRx during the 1st quarter valued at $33,000. SG Americas Securities LLC acquired a new stake in OptimizeRx during the 4th quarter valued at $51,000. Wells Fargo & Company MN lifted its holdings in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in OptimizeRx during the 4th quarter valued at $81,000. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.